Clinical trial
Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
Recruiting now · Phase 3 · 1 countries · Registry ID NCT05569772
What this study is about
Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with similarly elevated glucose levels. Early intervention after the index pregnancy is therefore crucial to prevent T2DM. With the SERENA project, the investigators aim to reduce the risk to develop T2DM with the long-acting GLP-1 agonist semaglutide in women with a recent history of GDM and glucose intolerance in early postpartum.
Basic eligibility
Full registry criteria
Treatments and study arms
Semaglutide Pen Injector
maintenance dose of 1mg SC once weekly
Semaglutide placebo
maintenance dose of 1mg SC once weekly
Primary outcomes
Defined by FPG, OGTT, and/or HbA1c according to the ADA criteria
Study locations
13 locations were listed when this page was built. The first 40 are shown.